HEMOSTATIC SYSTEM ACTIVATION STUDY

止血系统激活研究

• 批准号: 2691794
• 负责人: J P KISTLER
• 金额: $ 14.13万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 1995
• 资助国家: 美国
• 起止时间: 1995-09-05 至 2001-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2691794
• 关键词: antithrombins; aspirin; cardiovascular disorder chemotherapy; cardiovascular disorder epidemiology; cerebral ischemia /hypoxia; clinical research; disease /disorder proneness /risk; drug resistance; hemostatics; human subject; human therapy evaluation; longitudinal human study; peptide analog; platelet aggregation inhibitors; prothrombin; radioimmunoassay; relapse /recurrence; stroke; thrombin; warfarin

The specific aim of the Hemostatic System Activation Study (HAS) is to investigate the level of activity of the hemostatic system in patients in the Warfarin Aspirin Recurrent Stroke Study (WARSS). The radioimmunoassay measurement of the peptide fragment F1+2, a by-product of the conversion of prothrombin to thrombin, will be the indicator of the level of activity of the hemostatic system. Whether or not antithrombotic therapy is more beneficial than antiplatelet therapy in preventing recurrent stroke, HAS will provide an analysis of the actual level of in vivo thrombin generation associated with the INR achieved in the WARSS population. A higher mean F1+2 is expected in the aspirin treated cryptogenic stroke patients as compared to the aspirin treated non-cryptogenic stroke patients. A lower mean F 1+2 in the warfarin treated patients as compared to those on aspirin is expected. Some patients, however, may be resistant to the antithrombotic effect of warfarin as measured by a high F 1+2 value when their INR is in the WARSS therapeutic range of 1.4 to 2.8. The INR should correlate inversely with the F 1+2 and HAS will assess whether that relationship is constant over time. The association between F 1+2 and vascular risk factors (age, sex, hypercholesterolemia, hypertension, diabetes, smoking) and primary and secondary stroke subtypes will be studied. Other aims are to correlate F 1+2 level with data obtained in the APASS, PICSS and GENESIS substudies of WARSS, thereby enhancing the information obtained from them.

止血系统激活研究的具体目的是 研究患者止血系统的活性水平 在华法林阿司匹林复发性中风研究（WARSS）中。 这 肽片段F1+2的放射免疫测定测量，副产品 将凝血酶原转化为凝血酶，将是 止血系统的活性水平。 是否 抗血栓疗法比抗血小板治疗更有益 防止复发性中风，将对实际分析 与INR相关的体内体内凝血酶生成水平 在战争中。 阿司匹林中预计会有更高的平均F1+2 与阿司匹林相比，治疗的隐源性中风患者 非晶状体中风患者。 华法林中的平均f 1+2较低 预计治疗的患者与阿司匹林相比。 一些 但是，患者可能对 由高f 1+2值衡量的华法林在其INR中 战争治疗范围为1.4至2.8。 INR应关联 与F 1+2相反，并将评估该关系是否 随着时间的流逝是恒定的。 F 1+2与血管风险之间的关联 因素（年龄，性别，高胆固醇血症，高血压，糖尿病， 将研究吸烟）以及初级和继发性中风子类型。 其他目的是将F 1+2级别与Apass中获得的数据相关联， 战争的图片和创世记，从而增强了信息 从他们那里获得。